• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Revelation Biosciences Inc. (Amendment)

    2/6/23 2:39:20 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REVB alert in real time by email
    SC 13G/A 1 paic13ga31dec2022.htm 10,011,662

                               

    ===============================================================================

                               

                                      UNITED STATES                                 

                           SECURITIES AND EXCHANGE COMMISSION                       

                                 WASHINGTON, D.C. 20549                             

                               

                                      SCHEDULE 13G/A                             

                               

                        Under the Securities Exchange Act of 1934                   

                                    (Amendment No.1)*                             

                             

                               

    REVELATION BIOSCIENCES, INC.

    -------------------------------------------------------------------------------

                                    (Name of Issuer)                                

                               

                               

    Common Stock, par value $0.0001 per share

    -------------------------------------------------------------------------------

                             (Title of Class of Securities)                         

                               


                                       76135L309

    -------------------------------------------------------------------------------

                                     (CUSIP Number)                                 

                               


    December 31, 2022

    -------------------------------------------------------------------------------

                 (Date of Event Which Requires Filing of This Statement)            

                               

    Check the appropriate box to designate the rule pursuant to which this Schedule

    is filed:                  

                                 [X] Rule 13d-1(b)                                  

                                 [ ] Rule 13d-1(c)                                  

                                 [ ] Rule 13d-1(d)                                  

                                           

    * The remainder of this cover page shall be filled out for a reporting person's

    initial filing on this form with respect to the subject class of securities, and

    for any subsequent   amendment   containing   information  which  would  alter

    disclosures provided in a prior cover page.                                     

                               

    The information required on the remainder of this cover page shall not be deemed

    to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of

    1934 ("Act") or otherwise subject to the liabilities of that section of the Act

    but shall be  subject  to all other  provisions  of the Act  (however, see the

    Notes).



    --------------------------------------------------------------------------------

    1.               NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION       

                      NO. OF ABOVE PERSON                                          

                               

                      WEISS ASSET MANAGEMENT LP                                  

    --------------------------------------------------------------------------------

    2.                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   

                     (A) [ ]  

                     (B) [ ]   

    --------------------------------------------------------------------------------

    3.                SEC USE ONLY                                                 

                               

                               

    --------------------------------------------------------------------------------

    4.                CITIZENSHIP OR PLACE OF ORGANIZATION                         

                               

                      DELAWARE

    --------------------------------------------------------------------------------

                                   5.     SOLE VOTING POWER                        

                               

                                          0                                        

       NUMBER OF                  --------------------------------------------------

        SHARES                     6.     SHARED VOTING POWER                      

     BENEFICIALLY              

    OWNED BY                          0               

     EACH                      --------------------------------------------------

      REPORTING                    7.     SOLE DISPOSITIVE POWER                  

       PERSON                  

        WITH:                             0                                       

                                  --------------------------------------------------

                                   8.     SHARED DISPOSITIVE POWER                

                               

                                          0

    --------------------------------------------------------------------------------

    9.                AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                               

                      0

    --------------------------------------------------------------------------------

    10.               CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES        

                      CERTAIN SHARES*                                          [ ]

    --------------------------------------------------------------------------------

    11.               PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)           

                               

                      0.00%     

    --------------------------------------------------------------------------------

    12.               TYPE OF REPORTING PERSON*                                  

                               

                      IA – Investment Adviser                             



    --------------------------------------------------------------------------------

    1.               NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION       

                      NO. OF ABOVE PERSON                                          

                               

                      WAM GP LLC                                  

    --------------------------------------------------------------------------------

    2.                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   

                     (A) [ ]  

                     (B) [ ]   

    --------------------------------------------------------------------------------

    3.                SEC USE ONLY                                                 

                               

                               

    --------------------------------------------------------------------------------

    4.                CITIZENSHIP OR PLACE OF ORGANIZATION                         

                               

                      DELAWARE

    --------------------------------------------------------------------------------

                                   5.     SOLE VOTING POWER                        

                               

                                          0                                        

       NUMBER OF                  --------------------------------------------------

        SHARES                     6.     SHARED VOTING POWER                      

     BENEFICIALLY              

    OWNED BY                          0               

     EACH                      --------------------------------------------------

      REPORTING                    7.     SOLE DISPOSITIVE POWER                  

       PERSON                  

        WITH:                             0                                       

                                  --------------------------------------------------

                                   8.     SHARED DISPOSITIVE POWER                

                               

                                          0

    --------------------------------------------------------------------------------

    9.                AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                               

                      0

    --------------------------------------------------------------------------------

    10.               CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES        

                      CERTAIN SHARES*                                          [ ]

    --------------------------------------------------------------------------------

    11.               PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)           

                               

                      0.00%     

    --------------------------------------------------------------------------------

    12.               TYPE OF REPORTING PERSON*                                  

                               

                      HC – Parent Holding Company/Control Person                            





    --------------------------------------------------------------------------------

    1.               NAME OF REPORTING PERSON/S.S. OR I.R.S. IDENTIFICATION      

                      NO. OF ABOVE PERSON                                         

                               

                      ANDREW M. WEISS, PH.D.                                      

    --------------------------------------------------------------------------------

    2.                CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   

                      (A) [ ]

                      (B) [ ]   

    --------------------------------------------------------------------------------

    3.                SEC USE ONLY                                                

                               

                               

    --------------------------------------------------------------------------------

    4.                CITIZENSHIP OR PLACE OF ORGANIZATION                        

                               

                      USA      

    --------------------------------------------------------------------------------

                                   5.     SOLE VOTING POWER                       

                               

                                          0                                       

       NUMBER OF                  --------------------------------------------------

        SHARES                     6.     SHARED VOTING POWER                      

     BENEFICIALLY              

    OWNED BY                          0               

     EACH                      --------------------------------------------------

      REPORTING                    7.     SOLE DISPOSITIVE POWER                  

       PERSON                  

        WITH:                             0                                       

                                  --------------------------------------------------

                                   8.     SHARED DISPOSITIVE POWER               

                               

                                          0

    --------------------------------------------------------------------------------

    9.                AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

                               

                      0

    --------------------------------------------------------------------------------

    10.               CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES       

                      CERTAIN SHARES*                                          [ ]

    --------------------------------------------------------------------------------

    11.               PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)           

                               

                      0.00%    

    --------------------------------------------------------------------------------

    12.               TYPE OF REPORTING PERSON*                                  

                               

                      HC – Parent Holding Company/Control Person       




    ITEM 1.                    

                               

          (a) Name of Issuer:  REVELATION BIOSCIENCES, INC.

                             ------------------------------------------------

                              

          (b) Address of Issuer's Principal Executive Offices:    

    4660 La Jolla Village Drive, Suite 100,

    San Diego, CA

                    

         ------------------------------------------------                   


    ITEM 2.                    

                               

          (a) and (c): Name and Citizenship of Persons Filing:                    

                               

     (i)  Weiss Asset Management LP, a Delaware limited partnership ("Weiss        Asset Management").

    (ii)   WAM GP LLC, a Delaware limited liability company (“WAM GP”).

           (iii)  Andrew M. Weiss, Ph.D., a United States citizen (“Andrew Weiss”).      

                               

          (b):  Address of Principal Business Office:                            

                               

          Weiss Asset Management, WAM GP, and Andrew Weiss have a business    

          address of 222 Berkeley St., 16th floor, Boston, Massachusetts 02116

                               

          (d) Title of Class of Securities: Common Stock, par value $0.0001 per share

             

    -------------------------------------                        

          (e) CUSIP Number: 76135L309

                           ------------------                      

                 

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B), CHECK

            WHETHER THE PERSON FILING IS A:                                         

                               

         (a)  [ ] Broker or Dealer registered under Section 15 of the Act           

                  (15 U.S.C. 78o).                                                  

         (b)  [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).    

         (c)  [ ] Insurance Company as defined in section 3(a)(19) of the Act       

                  (15 U.S.C. 78c).                                                  

         (d)  [ ] Investment  Company  registered  under section 8 of the Investment

                  Company Act of 1940 (15 U.S.C. 80a-8).                            

         (e)  [X] Investment  Adviser registered under section 203 of the Investment

                  Advisers Act or under the laws of any State                       

         (f)  [ ] Employee  Benefit  Plan,  Pension  fund  which is  subject to the

                  provisions of the Employee  Retirement  Income Security Act of    

                  1974 or Endowment Fund; see Section 240.13d-1(b)(1)(ii)(F)        

         (g)  [X] A Parent Holding Company  or  control  person, in  accordance with

                  Section 240.13d-1(b)(ii)(G)                     

         (h)  [ ] A Savings  Association  as defined in Section  3(b) of the Federal

                  Deposit Insurance Act (12 U.S.C. 1813)                            

         (i)  [ ] A  Church  Plan  that  is  excluded  from  the  definition  of  an

                  investment  company under Section  3(c)(14) of the Investment     

                  Company Act of 1940 (15 U.S.C. 80a-3)                             

         (j)  [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J)          

                             


      




    ITEM 4.   OWNERSHIP        

                               

    WEISS ASSET MANAGEMENT*                                             

          (a) Amount Beneficially Owned:  0

                                         -------------------------------------------

          (b) Percent of Class:  0.00%                                               

                                ----------------------------------------------------

          (c) Number of shares as to which such person has:                         

                               

            (i)   sole power to vote or to direct the vote:   0                    

                                                             -----------------------

            (ii)  shared power to vote or to direct the vote:  0

                                                               ---------------------

            (iii) sole power to dispose or to direct the disposition of:  0         

                                                                          ----------

            (iv)  shared power to dispose or to direct the disposition of: 0

                                                                           ----------                  


    WAM GP*                                             

          (a) Amount Beneficially Owned:  0

                                         -------------------------------------------

          (b) Percent of Class:  0.00%                                            

                                ----------------------------------------------------

          (c) Number of shares as to which such person has:                         

                               

            (i)   sole power to vote or to direct the vote:    0                    

                                                             -----------------------

            (ii)  shared power to vote or to direct the vote:  0

                                                               ---------------------

            (iii) sole power to dispose or to direct the disposition of:  0         

                                                                          ----------

            (iv)  shared power to dispose or to direct the disposition of: 0

                                                                           ----------                     


      ANDREW M. WEISS, PH.D.*                         

          (a) Amount Beneficially Owned:  0

                                         -------------------------------------------

          (b) Percent of Class:  0.00%                                           

                                ----------------------------------------------------

          (c) Number of shares as to which such person has:                         

                               

            (i)  sole power to vote or to direct the vote:    0                    

                                                            ------------------------

            (ii) shared power to vote or to direct the vote:  0

        

        -----------------------

            (iii) sole power to dispose or to direct the disposition of:   0         

                    

       -----------

            (iv) shared power to dispose or to direct the disposition of: 0

                                                                          -----------

    -----------------------    

    * Weiss Asset Management is the sole investment manager to a private investment partnership, (the “Partnership”) and private investment funds (“Funds”). WAM GP is the sole general partner of Weiss Asset Management. Andrew Weiss is the managing member of WAM GP. Shares reported for WAM GP, Andrew Weiss and Weiss Asset Management include shares beneficially owned by the Partnership and the Funds.

    Each of WAM GP, Weiss Asset Management, and Andrew Weiss disclaims beneficial ownership of the shares reported herein as beneficially owned by each except to the extent of their respective pecuniary interest therein. The percent of class computations are based on 23,536,070 shares of Common Stock, par value $0.0001 per share, as of November 7, 2022 as reported on the Form 10-Q of the Issuer, which was filed with the SEC on November 11, 2022.



    ITEM 5.   OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS                         

                               

             If this statement is being filed to report the fact that as of the date

    hereof the reporting person has ceased to be the beneficial  owner of more than

    five percent of the class of securities, check the following [X].

                               

                               

    ITEM 6.   OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON       

                               

          Not Applicable       

                               

                               

    ITEM 7.  IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE

             SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL

             PERSON            

                               

          See Item 4.       

                               

                               

    ITEM 8.   IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP             

                               

          Not Applicable       



    ITEM 9.   NOTICE OF DISSOLUTION OF GROUP                                        

                               

          Not Applicable                                  



    ITEM 10.  CERTIFICATION    

                               

    By signing below I certify that, to the best of my knowledge and belief, the

    securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.    



    ITEM 11.  MATERIALS TO BE FILED AS EXHIBITS


    Exhibit 1

    Joint Filing Agreement    


      SIGNATURE                                   

                               

    After reasonable inquiry and to the best of my knowledge and belief, I hereby

    certify that the information set forth in this statement is true, complete and

    correct.                   

                               

    Dated:  February 6, 2023     

                               WEISS ASSET MANAGEMENT LP            


    By:  /s/ Mary Ferruolo              

    -----------------------------------

    Mary Ferruolo, Authorized Signatory



    WAM GP LLC

        

    By:  /s/ Mary Ferruolo                          

    -----------------------------------

    Mary Ferruolo, Authorized Signatory



    ANDREW M. WEISS, PH.D.                         

        

    By:  /s/ Mary Ferruolo                         

    -----------------------------------

    Mary Ferruolo, Attorney-in-Fact for Andrew Weiss***


    _____

    *** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on February 3, 2023 in respect of its holding in DEEP MEDICINE ACQUISITION CORP.



    Exhibit 1

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, Weiss Asset Management LP, WAM GP LLC, and Andrew M. Weiss, hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G and/or 13D (including any and all amendments thereto) with respect to the Common Stock, par value $0.0001 per share of REVELATION BIOSCIENCES, INC. (FORMERLY KNOWN AS PETRA ACQUISITION INC.) and further agree that this Joint Filing Agreement, as may be amended from time to time, shall be included as an Exhibit to such joint filings.

     

    The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and/or 13D and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

     

    This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

     

    IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 9, 2022.


                               WEISS ASSET MANAGEMENT LP            


    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer


                                                                                                             

    WAM GP LLC

        

    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Chief Compliance Officer



    ANDREW M. WEISS, PH.D.                         

        

    By:  /s/ Georgiy Nikitin              

    -----------------------------------

    Georgiy Nikitin, Attorney-in-Fact for Andrew Weiss**


    _____

    ** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on January 25, 2017 in respect of its holding in Quinpario Acquisition Corp. 2.



    Get the next $REVB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $REVB

    DatePrice TargetRatingAnalyst
    2/17/2022$12.00Buy
    Roth Capital
    More analyst ratings

    $REVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on Revelation Biosciences with a new price target

      Roth Capital initiated coverage of Revelation Biosciences with a rating of Buy and set a new price target of $12.00

      2/17/22 8:17:25 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chawla Lakhmir S was granted 181 shares (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:14:40 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Carver Jennifer was granted 181 shares, increasing direct ownership by 3,017% to 187 units (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:12:17 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Roper Jess was granted 181 shares, increasing direct ownership by 9,050% to 183 units (SEC Form 4)

      4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

      2/13/25 6:09:20 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

      – Sample analysis and data collection ongoing – – Data expected during Q3 2025 – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). As planned, a total of 5 cohorts were enrolled at 3 clinics in the United States. Several study data sets are expected during Q3 2025: these will include safety parameters, changes in hematologic pa

      7/16/25 9:00:00 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse stock split will be effective as of the morning of July 7, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol "REVB." The CUSIP number for the common stock following the reverse stock split will be 76135L705. The reverse stock split is intended to increase the market price per share of the Company's common stock to reg

      7/1/25 5:26:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years

      5/29/25 4:05:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    SEC Filings

    See more
    • Revelation Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      7/9/25 4:17:31 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      6/25/25 4:26:46 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Revelation Biosciences Inc.

      DEF 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      6/9/25 4:51:25 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Financials

    Live finance-specific insights

    See more
    • Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients "While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe bu

      5/8/25 4:15:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FDA Acceptance of Gemini IND Received net proceeds of $3.7 million from the exercise of warrants in December 2024 "We made significant progress at the end of last year and hope to continue that pace in 2025," said James

      3/6/25 4:15:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Received net proceeds of $3.8 million from the exercise of warrants in August 2024 Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers "The Revelation team continues to make significan

      11/8/24 4:15:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Leadership Updates

    Live Leadership Updates

    See more
    • Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

      Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

      5/23/25 4:05:00 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

      – A vote for Proposal 2 saves the Company over $200,000 per year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All proposals in the proxy are important and the Board of Directors has suggested a vote for all proposals. Please vote by calling Advantage Pr

      1/13/25 6:00:00 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

      Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company's Board of Directors (Board). "We are excited to welcome Dr. Chawla as an independent director to our Board," said James Rolke, Chief Executive Officer of Revelation. "Dr. Chawla brings decades of expertise and leadership in key areas such as nephrology, critical care medicine, drug development and strategic implementation. I am confident that he will provide valuable perspectives as we continue to execute our str

      10/2/23 9:00:00 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $REVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Revelation Biosciences Inc. (Amendment)

      SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

      2/13/24 8:12:05 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Revelation Biosciences Inc.

      SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

      1/3/24 8:36:37 AM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Revelation Biosciences Inc.

      SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

      2/21/23 4:49:56 PM ET
      $REVB
      Biotechnology: Pharmaceutical Preparations
      Health Care